Robert Boothroyd

Dr. Robert Boothroyd joined Inhibrx in January 2022 and is responsible for Medical Affairs and Business Development. Dr. Boothroyd brings over 12 years of clinical and pharmaceutical industry experience in both hematology and oncology.

Prior to joining Inhibrx, Dr. Boothroyd held various roles in large pharma including roles within Medical Affairs and Marketing. Most recently, he was U.S. Marketing Lead at Merck, responsible for the Lung and Thoracic Cancer indications including its blockbuster drug, KEYTRUDA® (pembrolizumab). Prior to Merck, Dr. Boothroyd spent 8 years at Novartis Oncology where he held diverse roles of increasing responsibility in both Global Medical Affairs and Marketing. These roles included working on a wide range of launches in both the hematology and oncology space, specifically ADAKVEO® (crizanlizumab) in Sickle Cell Disease, KISQALI® (ribociclib) in HR+ breast cancer, JAKAVI® (ruxolitinib) in polycythemia vera and myelofibrosis, and TASIGNA® (nilotinib) in chronic myeloid leukemia.

Dr. Boothroyd received his PharmD from Massachusetts College of Pharmacy in Boston, MA and completed his Post-Doctoral Fellowship from Rutgers University.